Webinar: Optimizing Approaches to Make Cell Therapies for Diabetes a Reality
Wednesday, June 12 | 12pm ET/9am PT | Online
Optimizing Approaches to Make Cell Therapies for Diabetes a Reality
At this webinar, attendees can expect to:
-
Gain insights into the latest advancements and ongoing progress in clinical trials focusing on Cell Therapies for Type 1 diabetes.
-
Explore the application of pluripotent or iPSc cells in product development for diabetes treatment, alongside the challenges encountered by researchers in manufacturing these therapies.
-
Understand the regulatory landscape governing diabetes treatments in both the United States and Canada, highlighting similarities, differences, and implications for product approval and oversight.
-
Investigate the support systems and resources available to foster innovation in the global diabetes sector, with a particular emphasis on initiatives backing newer approaches such as cell therapies.
Meet the Speakers
Dr. Jeffrey Millman, PhD
Washington University
Dr. Jeffrey Millman is currently an Associate Professor of Medicine and Biomedical Engineering at Washington University School of Medicine. He received his Ph.D. from MIT and completed his postdoctoral training at Harvard University. His current research is focused on synergizing both biomedical engineering and cell biology approaches to use stem cells for the study and treatment of diabetes. He is developing new approaches for the differentiation of insulin-producing islets from stem cells and improving their utility for cell replacement therapy and in vitro disease models. His innovations have been licensed to biotechnology companies in the diabetes space and resulted in ongoing clinical trials. Dr. Millman previously served as the vice president of research at Sana Biotechnology where he oversaw the preclinical development of hypoimmune stem cell-derived islets for the treatment of type 1 diabetes. His laboratory is supported by the NIH NIDDK and JDRF, and his scholarship has been recently recognized by awards from the JDRF, American Institute of Chemical Engineering, and the Biomedical Engineering Society.
Modestus Obochi, PhD, MBA
Chief Business Officer of Sernova
Sernova (TSX: SVA; OTCQB: SEOVF; FSE/XETRA: PSH) is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. The Company is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell Pouch System™, a novel implantable and scalable cell therapy platform transplanted initially with human donor islets but ultimately using an iPSC islet like cluster technology exclusively licensed from Evotec SE.
Access this on-demand recording today
Important Registration Note: We kindly suggest confirming in advance that your Zoom sign-in works and that your Zoom software is up to date. If you do not have a commercial Zoom account, please create a FREE account here.